DNAP MADE THE FRONT PAGE OF THE TAMPA BAY NEWSPAPER..
dbusiness.com
DNAPrint genomics tracks 2,000th genetic spoor
Aug 24, 2000 01:04 PM ET
--------------------------------------------------------------------------------
By Karen J. Cohen, dbusiness.com
--------------------------------------------------------------------------------
SARASOTA, Fla., Aug. 24 (dbusiness.com) -- DNAPrint genomics Inc. said this week it had reached a total of 2,000 specific polymorphisms in its search for genetic bits that have a role in certain reactions or diseases.
The firm is compiling a database, called the Phenome database, that focuses on particular genetic markers thought to be associated with liver problems for some people who take a class of anti-cholesterol drugs. Indications also suggest these same genes could be involved in some cancers.
A polymorphism is a genetic variation. The company, founded last year, is engaged in the emerging pharmacogenetics field - the genetic approach to drug design. Its plan is to study the DNA of those whose livers cannot tolerate drugs commonly prescribed for high cholesterol. Using an algorithmic database, the company expects that by examining a high number of samples, its researchers will be able to deduce which genes these people share. That way, doctors could avoid prescribing the drugs for the at-risk population.
Co-founder and chief scientific officer Tony Frudakis explained that while the government-funded Human Genome Project and other private firms are looking at the big DNA picture, few firms are concentrating on making detailed maps of a small number of genes. The firm looked at about 100 samples to find the 2,000 differentials. In each sample, researchers have found anywhere between five and 30 of the polymophisms, or significant variations.
"It's the difference between looking at the map of the United States and a detailed map of a city," he said. "We think our map is going to be the best for populations study."
A consortium of pharmaceutical firms are working on the SNP ("snip") map, looking for smaller markers in the DNA universe. While this project will eventually be in the public domain, it will not include the detail of DNAPrint's proprietary cartography, Frudakis said.
Using their information, the firm will be able to perform an efficacy study, by tracking over time patients with certain polymorphisms to more closely investigate how such genes function.
DNAPrint is looking at cancer as well because researchers reason that a gene which may delay the metabolism and excretion of a drug may also be slow to rid the body of toxic substances.
DNAPrint (Pink Sheets: DNAP) was started with $1 million in seed capital from Tampa Bay Financial and investments by the founders. The firm expects to make money through licensing and by eventually charging doctors a fee to run DNA tests on their patients.
Its stock was unchanged at midday at 11 cents per share.
Karen J. Cohen is a staff writer for dbusiness.com. E-mail her with story ideas and comments.
WEEEEEEEEEEEEEEEEEEEEEEEEEE!!!!!!!!!!!!!!!!!!!!!!!!! |
